Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
26 hedge funds and large institutions have $16.9M invested in Cidara Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 29 closing their positions.
29.84% more ownership
Funds ownership: 1.22% → 31.06% (+30%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less capital invested
Capital invested by funds: $20.3M → $16.9M (-$3.42M)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
48% less funds holding
Funds holding: 50 → 26 (-24)
83% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$4.8M |
| 2 |
CC
Checkpoint Capital
San Francisco,
California
|
+$1.99M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$181K |
| 4 |
BlackRock
New York
|
+$174K |
| 5 |
WIA
Wetzel Investment Advisors
Indianapolis,
Indiana
|
+$52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.15M |
| 2 |
Renaissance Technologies
New York
|
-$441K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$420K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$291K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$150K |
CDTX Hedge Fund Activity: Q2 2024 in Review
26 of the 6,934 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2024, worth a combined $16.9M — down 17% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CDTX and 5 opened new positions — a net loss of 24 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Monashee Investment Management, adding an estimated $4.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.15M sold.
- 26 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2024, down from 50 in Q1 2024.
- Funds reported $16.9M of Cidara Therapeutics stock for Q2 2024, down 17% quarter-over-quarter.
- 5 funds opened new Cidara Therapeutics positions in Q2 2024 and 29 closed out, a net change of -24 holders.
- The largest Cidara Therapeutics buyer in Q2 2024 was Monashee Investment Management, an estimated $4.8M added.
- The largest Cidara Therapeutics seller in Q2 2024 was Point72 Asset Management, an estimated $1.15M sold.
Based on aggregated 13F filings for Q2 2024.